Iovance Biotherapeutics: Base-Case Q3 Report Keeps 'Show Me' Mode [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Q3 revenue landed in the base case at $68 million, missing estimates, while gross margin improved to 29.6% (=30% adjusted for D&A). Management reaffirmed FY25 revenue guidance and extended cash runway to Q2 2027, but execution and credibility issues persist. Near-term upside is capped; IOVA needs two quarters of =$75M revenue and =35% gross margin (ex-D&A) to reconsider the rating. yuriz/iStock via Getty Images Stock Rally Meets A “Show Me” Setup Iovance Biotherapeutics' stock ( IOVA ) rallied after reporting Q3 earnings. My last assessment of IOVA followed its Q2 earnings report, which featured “weak” gross margins and a recent $350 million ATM equity program This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for i
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (NASDAQ:IOVA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? [Yahoo! Finance]Yahoo! Finance
- Is Iovance Biotherapeutics (IOVA) Undervalued? A Fresh Look at Valuation After Recent Share Price Rebound [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics (NASDAQ:IOVA) had its price target lowered by analysts at Chardan Capital from $20.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
IOVA
Earnings
- 11/6/25 - Beat
IOVA
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- IOVA's page on the SEC website